Harrow, Inc. Files 8-K on Financial Obligations
Ticker: HROW · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1360214
| Field | Detail |
|---|---|
| Company | Harrow, INC. (HROW) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001, $40.0 million, $250.0 m, $250.0 million, $4.3 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt, financing, material-agreement
TL;DR
Harrow Inc. just filed an 8-K about its senior notes due 2026 & 2027 - check the details!
AI Summary
On September 5, 2025, Harrow, Inc. entered into a material definitive agreement related to its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
Why It Matters
This filing signals potential changes or confirmations regarding Harrow's debt obligations, which could impact its financial health and investor confidence.
Risk Assessment
Risk Level: medium — Filings related to material definitive agreements and financial obligations can introduce uncertainty or confirm existing risks for a company.
Key Numbers
- 8.625% — Senior Notes Interest Rate (Interest rate on notes due 2026)
- 2026 — Maturity Year (Maturity year for 8.625% Senior Notes)
- 11.875% — Senior Notes Interest Rate (Interest rate on notes due 2027)
- 2027 — Maturity Year (Maturity year for 11.875% Senior Notes)
Key Players & Entities
- HARROW, INC. (company) — Filer
- Harrow Health, Inc. (company) — Former Company Name
- Imprimis Pharmaceuticals, Inc. (company) — Former Company Name
- TRANSDEL PHARMACEUTICALS INC (company) — Former Company Name
- 8.625% Senior Notes due 2026 (dollar_amount) — Financial Obligation
- 11.875% Senior Notes due 2027 (dollar_amount) — Financial Obligation
FAQ
What specific material definitive agreement was entered into by Harrow, Inc. on September 5, 2025?
The filing indicates a material definitive agreement related to its 8.625% Senior Notes due 2026 and 11.875% Senior Notes due 2027.
What is the nature of the financial obligation created by Harrow, Inc. as reported in this 8-K?
The filing states the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.
What were Harrow, Inc.'s former company names?
Harrow, Inc. was formerly known as Harrow Health, Inc., Imprimis Pharmaceuticals, Inc., and TRANSDEL PHARMACEUTICALS INC.
When did Harrow, Inc. change its name from Harrow Health, Inc.?
The date of name change from Harrow Health, Inc. was December 28, 2018.
What is Harrow, Inc.'s Standard Industrial Classification code?
Harrow, Inc.'s Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
Filing Stats: 2,115 words · 8 min read · ~7 pages · Grade level 13 · Accepted 2025-09-08 08:01:14
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HROW The Nasdaq
- $40.0 million — Third has committed to provide up to a $40.0 million senior secured revolving credit facilit
- $250.0 m — te proceeds in the Offering of at least $250.0 million, repayment of outstanding indebte
- $250.0 million — nnounce the launch of its offer to sell $250.0 million aggregate principal amount of senior un
- $4.3 million — n initial cash payment of approximately $4.3 million at closing and contingent consideration
Filing Documents
- form8-k.htm (8-K) — 62KB
- ex99-1.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- 0001493152-25-012778.txt ( ) — 317KB
- hrow-20250905.xsd (EX-101.SCH) — 4KB
- hrow-20250905_def.xml (EX-101.DEF) — 26KB
- hrow-20250905_lab.xml (EX-101.LAB) — 36KB
- hrow-20250905_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARROW, INC. Dated: September 8, 2025 By: /s/ Andrew R. Boll Andrew R. Boll President and Chief Financial Officer